12. Experimental Treatments: Psilocybin
Key Points
- Psilocybin is a psychedelic agent with 5-HT2A agonist properties
- An open-label study in 12 patients showed that psilocybin produced improvement rapid improvement that lasted up to three months in half the group
- There are practical challenges around research and potential therapeutic use.
- Further research seems worthwhile.
- There are practical challenges around research and potential therapeutic use.
To unlock this video you need to become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.
Check Our CME ProgramDownloads for Offline Access
- Download Video (MP4)
- Download Audio File (MP3)
- Download Presentation File (PPTX)
